Testosterone Cypionate Label Updates 2020 to 2026

Regulatory History Before 2020: The Foundation

Testosterone cypionate received FDA approval in 1979 under the brand name Depo-Testosterone. For decades, its label stayed relatively static. That changed sharply in the mid-2010s. The FDA issued a Safety Communication in March 2015 requiring all testosterone product labels to carry a warning about possible increased cardiovascular risk, specifically heart attack and stroke. This same action narrowed the approved indication: testosterone cypionate was no longer labeled for age-related testosterone decline alone, but restricted to men with hypogonadism caused by documented conditions of the hypothalamus, pituitary, or testes [1].

In October 2016, the FDA mandated class-wide labeling changes addressing abuse and dependence potential for all anabolic androgenic steroids, including testosterone cypionate. The Controlled Substances Act classification as Schedule III had been in place since 1991, but the label language around misuse had been minimal until this revision [2].

A 2018 label update added venous thromboembolism (VTE) to the Warnings and Precautions section after FDA's Sentinel System analysis detected a signal for deep vein thrombosis and pulmonary embolism in testosterone users [3]. By the end of 2019, the testosterone cypionate label carried cardiovascular, VTE, and abuse warnings. The stage was set for the more data-driven revisions that followed.

The TRAVERSE Trial: The Catalyst for Post-2020 Label Changes

The single most consequential event shaping testosterone cypionate labeling after 2020 was the TRAVERSE trial (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men). Published in the New England Journal of Medicine in June 2023, TRAVERSE enrolled 5,246 men aged 45 to 80 with pre-existing or high risk of cardiovascular disease and serum testosterone below 300 ng/dL [4].

The primary endpoint was time to first major adverse cardiovascular event (MACE): a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. The hazard ratio was 0.99 (95% CI 0.81 to 1.21), meeting the pre-specified non-inferiority margin of 1.5. Testosterone did not increase MACE. This was a relief. But it was not a clean bill of health.

TRAVERSE also found higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone arm. The atrial fibrillation signal (HR 1.26 to 95% CI 0.90 to 1.77) was not statistically significant but prompted FDA reviewers to request additional analyses [4]. Polycythemia (hematocrit >54%) occurred in 3.5% of testosterone-treated men versus 0.1% on placebo, confirming a risk already suspected from smaller studies and the Testosterone Trials (TTrials) [5].

2023 Label Revision: Abuse and Dependence Language Expansion

The FDA required updated Abuse and Dependence sections across all testosterone product labels in 2023. For testosterone cypionate, the revised Section 9 now includes quantified estimates of androgen abuse prevalence drawn from NIDA epidemiologic data and post-marketing adverse event reports [6]. The previous language had described abuse potential in qualitative terms ("has been reported"). The 2023 revision provides dose ranges associated with supraphysiologic use, withdrawal symptom profiles (fatigue, depressed mood, decreased libido, insomnia), and the explicit statement that psychological dependence can develop.

The Endocrine Society's 2018 Clinical Practice Guideline already recommended against prescribing testosterone to men without a confirmed diagnosis of hypogonadism through repeat morning serum testosterone measurements [7]. The label now aligns more closely with this recommendation by emphasizing in Section 1 (Indications and Usage) that testosterone cypionate is "not indicated for age-related hypogonadism" and that two morning samples below the laboratory reference range are required before initiating therapy.

This revision also carried practical prescribing implications. State prescription drug monitoring programs (PDMPs) already track Schedule III substances, but several states, including Ohio and Kentucky, issued pharmacy board guidance referencing the updated abuse language as grounds for additional verification steps on testosterone prescriptions [8].

2024 Cardiovascular Label Update: What TRAVERSE Changed

Following an FDA Advisory Committee meeting in September 2023, where committee members voted 13 to 3 that the TRAVERSE data supported modifying the existing cardiovascular warning, the FDA finalized a revised cardiovascular risk statement for testosterone cypionate in early 2024 [9].

The previous warning, in place since 2015, stated that testosterone "may increase the risk of heart attack and stroke." The 2024 revision replaced this with more specific language. It now states that the TRAVERSE trial did not demonstrate increased MACE risk in hypogonadal men at high cardiovascular risk, but notes that the study was not powered to evaluate individual components of the composite endpoint, and that signals for atrial fibrillation and thromboembolic events require ongoing surveillance [4][9].

The practical effect: the label no longer implies a generalized cardiovascular danger signal. "The 2015 warning was based on observational data with significant confounding," noted Dr. Shalender Bhasin, TRAVERSE principal investigator, in the NEJM editorial accompanying the trial results. "TRAVERSE provides Level 1 evidence that testosterone replacement does not increase short-term MACE risk in this population" [4].

For prescribers, this means cardiovascular disease alone is no longer a contraindication to testosterone therapy. The label still advises evaluating cardiovascular risk factors before initiation and monitoring blood pressure and lipids, but the tone shifted from precautionary to evidence-contextualized.

Polycythemia and Hematocrit Monitoring: The Reinforced Warning

Polycythemia has been listed as an adverse reaction on the testosterone cypionate label since at least 2004. But the post-2020 revisions gave it more prominence. The current label specifies a hematocrit threshold of 54%, above which dose reduction or treatment interruption is recommended [10]. This aligns with the American Urological Association's 2018 guideline, which recommends checking hematocrit at baseline, at 3 to 6 months, and then annually [11].

TRAVERSE quantified the magnitude: 3.5% of testosterone-treated men developed hematocrit above 54%, compared with 0.1% on placebo. Earlier, the TTrials (N=790) showed testosterone gel raised hematocrit by a mean of 2.6 percentage points over 12 months [5]. The injectable cypionate ester produces higher peak serum concentrations than topical formulations, and the polycythemia risk with intramuscular injection appears correspondingly greater.

The reinforced warning also now recommends against initiating testosterone cypionate in men with baseline hematocrit above 50% without hematology consultation. This threshold was not previously specified in the label text. It reflects consensus from the Endocrine Society guideline and mirrors clinical practice patterns documented in a 2022 Veterans Affairs retrospective cohort study (N=83,010) published in JAMA Internal Medicine that found 6.2% of testosterone-treated veterans developed polycythemia within the first year [12].

Venous Thromboembolism: Retained and Reinforced

The 2018 VTE warning survived every subsequent revision unchanged in substance, though it gained supporting data. The FDA's Sentinel analysis had originally detected a 1.3-fold increased risk of VTE in the first six months after testosterone initiation compared to non-users [3]. TRAVERSE reinforced this: the pulmonary embolism rate was numerically higher in the testosterone group (0.9% vs. 0.5%), though the difference did not reach statistical significance (HR 1.49 to 95% CI 0.83 to 2.67) [4].

The current label recommends evaluating patients for VTE risk factors (obesity, immobilization, personal or family history of thrombosis, known thrombophilia) before starting testosterone cypionate. It does not mandate thrombophilia testing, consistent with the Endocrine Society position that routine screening is not cost-effective in this population [7].

One specific note: the label distinguishes between polycythemia-mediated thrombotic risk and VTE risk that may be independent of hematocrit elevation. This distinction matters clinically. A patient who develops polycythemia may have a compounded VTE risk, and the label advises dose adjustment in that scenario rather than simple monitoring.

Hepatotoxicity Warning: Unchanged but Contextualized

Testosterone cypionate carries a Warnings section on hepatic adverse effects, including peliosis hepatis. This language has not been modified since the 2015 revision cycle and pre-dates the 2020 to 2026 window. It originated from case reports associated primarily with oral 17-alpha-alkylated androgens (methyltestosterone, fluoxymesterone), not injectable esters [13].

The clinical relevance to testosterone cypionate is low. No cases of peliosis hepatis have been attributed to injectable testosterone cypionate in the FDA Adverse Event Reporting System (FAERS) public dashboard through 2025 [14]. The Endocrine Society guideline does not recommend routine liver function monitoring for patients on injectable testosterone [7]. The hepatotoxicity language remains as a class-wide artifact, and no post-2020 label revision has removed or modified it.

Compounding Pharmacy Regulatory Developments

While not a label change per se, FDA regulatory actions between 2020 and 2026 affected testosterone cypionate access through compounding pharmacies. The FDA issued warning letters to multiple 503B outsourcing facilities between 2021 and 2024 for manufacturing testosterone cypionate under conditions that did not meet current good manufacturing practice (cGMP) standards [15]. Several facilities received Form 483 observations related to sterility assurance failures in multi-dose vials.

In 2023, the FDA clarified that testosterone cypionate is not on the drug shortage list and is "essentially a copy" of a commercially available product when compounded by 503B facilities without a clinical difference, raising questions about the legal basis for outsourcing facility production under Section 503B of the FD&C Act [15]. This regulatory posture affected pricing and availability of compounded testosterone cypionate, particularly for cash-pay patients and telehealth-prescribing models.

What Prescribers Should Do Now

The cumulative effect of these label revisions creates a specific pre-initiation and monitoring checklist. Before prescribing testosterone cypionate, confirm hypogonadism with two morning serum total testosterone levels below 300 ng/dL. Check baseline hematocrit (do not initiate if above 50% without hematology input). Assess cardiovascular risk factors, VTE history, and screen for sleep apnea, which the label lists as a precaution [10].

After initiation, measure hematocrit at 3 to 6 months and annually thereafter. Repeat serum testosterone at trough (typically day 7 of a weekly or day 14 of a biweekly injection cycle) to confirm levels remain within the target range of 400 to 700 ng/dL per Endocrine Society recommendations [7]. Monitor blood pressure, lipid panel, and PSA per age-appropriate screening guidelines from the American Urological Association [11]. If hematocrit exceeds 54%, reduce the dose or suspend therapy until hematocrit falls below 50%.